Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Contineum Therapeutics granted stock options to Chief Scientific Officer Lorrain Daniel S. on January 30, 2026 under its 2024 Equity Incentive Plan. The award covers options to buy 160,000 shares of Class A common stock at an exercise price of $14.26 per share, expiring on January 29, 2036. These options vest in equal monthly installments over 48 months, conditioned on the executive’s continued service.
An additional grant of stock options to purchase 6,500 shares of Class A common stock at $14.26 per share was made in connection with the continuous service of the executive’s spouse at the company. These options have the same 48‑month monthly vesting schedule and are reported as indirectly owned through the spouse.
Contineum Therapeutics executive Tim Watkins reported option exercises, share sales, and a new option grant. On 01/28/2026 he exercised 3,611 stock options at an exercise price of $4.50 per share, acquiring 3,611 shares of Class A common stock.
That same day, he sold 2,800 shares at a weighted average price of $14.0861 and 811 shares at a weighted average price of $14.4848, leaving no directly held common shares after the transactions. These sales were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.
In a separate transaction on 01/30/2026, Watkins received an award of 160,000 stock options with a $14.26 exercise price, expiring on 01/29/2036. These options vest in equal monthly installments over 48 months, subject to his continuous service.
Contineum Therapeutics, Inc. received an amended Schedule 13G/A showing that investment manager Franklin Advisers, Inc., a subsidiary of Franklin Resources, reports beneficial ownership of 1,879,367 shares of Class A common stock, representing 6.2% of the class.
Franklin Advisers has sole voting and sole dispositive power over these shares, which are held in client accounts, including investment companies and other managed portfolios. The filing states the position is held in the ordinary course of business and is not for the purpose of changing or influencing control of Contineum Therapeutics.
Contineum Therapeutics, Inc. adopted a 2026 Employment Inducement Equity Incentive Plan, initially reserving 750,000 shares of its Class A common stock for awards.
The plan’s terms are described as substantially similar to the company’s 2024 Equity Incentive Plan, except that incentive stock options cannot be issued and awards may only be granted to recipients eligible under applicable Nasdaq rules. It was approved by the Board without stockholder approval under Nasdaq Listing Rule 5635(c)(4).
Awards may be granted only to new employees or rehires in connection with the commencement of employment when the grant is an inducement material to joining the company. Full plan documents and related stock option and restricted stock unit agreement forms will be filed as exhibits to the company’s Form 10-K for the year ended December 31, 2025.
Contineum Therapeutics, Inc. completed an underwritten public offering of 7,346,938 shares of its Class A common stock at $12.25 per share. The underwriters purchased the shares at $11.515 per share, and Contineum estimates net proceeds of approximately $84.2 million, assuming no exercise of the underwriters’ option to buy more shares. The company granted the underwriters a 30-day option to purchase up to an additional 1,102,040 shares. The transaction was conducted under an effective Form S-3 shelf registration and closed on December 15, 2025.
Contineum also issued press releases announcing a proposed $75.0 million offering and the pricing of an upsized $90.0 million offering of Class A common stock, highlighting increased deal size as demand solidified.
Contineum Therapeutics, Inc. is offering 7,346,938 shares of its Class A common stock at a public price of $12.250 per share, for gross proceeds of $89,999,991 before fees and expenses. After underwriting discounts and estimated costs, the company expects net proceeds of approximately $84.2 million, or approximately $96.9 million if underwriters fully exercise their 30‑day option to buy up to 1,102,040 additional shares.
Contineum is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation and immunology, including lead candidates PIPE‑791 and PIPE‑307. It plans to use the cash, together with existing balances, to advance PIPE‑791, support other research and development, and for general corporate purposes, including potential acquisitions. After this offering, 30,446,111 shares of Class A common stock (or 31,548,151 shares if the option is fully exercised) and 6,083,338 shares of non‑voting Class B common stock will be outstanding, and the company believes this funding will support operations through mid‑2029.
Contineum Therapeutics is offering $75.0 million of its Class A common stock in an underwritten primary equity offering. The company may also grant the underwriters a 30-day option to purchase up to an additional $11.25 million of Class A shares.
As of September 30, 2025, Contineum had 23,099,173 shares of Class A common stock and 6,083,338 shares of non-voting Class B common stock outstanding. The company expects that net proceeds from this offering, combined with existing cash, cash equivalents and marketable securities, will fund operations through mid-2029, with a primary focus on advancing its PIPE-791 program, supporting other research and development, and general corporate purposes, including potential complementary product or technology acquisitions without binding commitments.
Contineum is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology indications and remains an emerging growth and smaller reporting company. It does not expect to pay cash dividends in the foreseeable future and cautions that future share issuances and sales, including under its at-the-market program after a 30-day pause, could pressure the market price of its Class A common stock.
Contineum Therapeutics, Inc. reported that on December 8, 2025 it submitted details of its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis to the ClinicalTrials.gov Protocol Registration and Results System, with posting to follow PRS approval.
The 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled study will evaluate once-daily PIPE-791 in about 324 IPF patients, focusing on safety and tolerability and the change from baseline in absolute forced vital capacity at week 26.
The company’s trial design and launch strategy draw on prior regulatory engagement and completed Phase 1 studies, and it expects to begin the trial internationally and add countries as regulatory approvals are obtained, with completion anticipated in June 2028.
Contineum Therapeutics, Inc. (CTNM) reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis. The company furnished this press release as Exhibit 99.1 to the report and incorporated it by reference, indicating that detailed clinical results are contained in that exhibit.
Contineum Therapeutics (CTNM) reported a Q3 2025 net loss of $12.8 million, driven by research and development of $11.0 million and general and administrative expense of $3.9 million. Interest income was $2.0 million, partially offsetting operating costs.
Liquidity remains strong with $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025. Management states these resources are sufficient for at least 12 months. During the quarter, the company activated its at-the-market program, selling 3,241,110 Class A shares at a weighted average price of $6.04 for $19.0 million in net proceeds.
Pipeline execution continued. PIPE-791 completed Phase 1 and Phase 1b PET work; a global Phase 2 in idiopathic pulmonary fibrosis is planned for Q4 2025, and an exploratory Phase 1b chronic pain trial began dosing in March 2025 with topline data expected in the first half of 2026. PIPE-307, partnered with J&J, has a fully enrolled Phase 2 RRMS trial with topline results targeted for Q4 2025, and J&J initiated a Phase 2 study in major depressive disorder in December 2024.